A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19
PHASE1
The primary goal for this study is to evaluate the safety and reactogenicit...
Status
Completed
Location
Synexus Clinical Research US Phoenix Southeast, Inc.
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
PHASE4
The purpose of this study is to evaluate the efficacy and safety of mRNA-12...